Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.

doi:10.1038/s41467-018-03170-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.

Nature communications - 20 Feb 2018

Herling Carmen D, Abedpour Nima, Weiss Jonathan, Schmitt Anna, Jachimowicz Ron Daniel, Merkel Olaf, Cartolano Maria, Oberbeck Sebastian, Mayer Petra, Berg Valeska, Thomalla Daniel, Kutsch Nadine, Stiefelhagen Marius, Cramer Paula, Wendtner Clemens-Martin, Persigehl Thorsten, Saleh Andreas, Altmüller Janine, Nürnberg Peter, Pallasch Christian, Achter Viktor, Lang Ulrich, Eichhorst Barbara, Castiglione Roberta, Schäfer Stephan C, Büttner Reinhard, Kreuzer Karl-Anton, Reinhardt Hans Christian, Hallek Michael, Frenzel Lukas P, Peifer Martin

Abstract excerpt

Deciphering the evolution of cancer cells under therapeutic pressure is a crucial step to understand the mechanisms that lead to treatment resistance. To this end, we analyzed whole-exome sequencing data of eight chronic lymphocytic leukemia (CLL) patients that developed resistance upon BCL2-inhibition by venetoclax. Here, we report recurrent mutations in BTG1 (2 patients) and homozygous deletions affecting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p15

Share to Cyclin-Dependent Kinase Inhibitor p16

Share to Cyclin-Dependent Kinase Inhibitor p18

Share to Drug Resistance, Neoplasm

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Neoplasm Proteins

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 29463802
DOI: 10.1038/s41467-018-03170-7
PMCID: PMC5820258

Genes

BCL2
BRAF
BTG1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.PMID 29463802Read ↗

Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samplesSemantic proximity Read ↗

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutationsSemantic proximity Read ↗

Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.Semantic proximity Read ↗

Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel AgentsSemantic proximity Read ↗

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.Semantic proximity Read ↗

Therapy-driven clonal dynamics in chronic lymphocytic leukemia.Semantic proximity Read ↗

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.Semantic proximity Read ↗

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclaxSemantic proximity Read ↗

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapySemantic proximity Read ↗

When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.